60° Pharmaceuticals (60P) was founded with the goal of developing medicines for tropical diseases, including those considered neglected by the World Health Organization. In 2018, we took a huge step toward meeting our goals when our first product was approved for use by the US Food and Drug Administration.1
ARAKODA® (tafenoquine) is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older.1
There has long been a need for new drugs for malaria prevention. Existing options:
ARAKODA® (tafenoquine) tablets, launched in 2019, meets all these needs.1
ARAKODA® should not be administered to:
Warnings and Precautions
The most common adverse reactions (incidence ≥1%) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams and anxiety.
Avoid co-administration with drugs that are substrates of organic cation transporter-2 (OCT2) or multidrug and toxin extrusion (MATE) transporters.
Use in Specific Populations
Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®.
To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals at 1-888-834-0225 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Cases and 1 Million+ deaths in the U.S. from COVID-19 infections
Annual deaths from malaria globally
Travelers to malaria endemic regions per annum
Annual dengue infections globally